TY - JOUR
T1 - Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients
AU - Morimoto, Hisanori
AU - Nakao, Kazushi
AU - Fukuoka, Kousuke
AU - Sarai, Ai
AU - Yano, Ai
AU - Kihara, Takashi
AU - Fukuda, Shinji
AU - Wada, Jun
AU - Makino, Hirofumi
PY - 2005/12
Y1 - 2005/12
N2 - Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and an independent predictor of overall mortality and cardiovascular outcome in haemodialysis (HD) patients. In the present study, we compared the effects of a vitamin E-coated polysulfone membrane (PSE) and a non-vitamin E-coated polysulfone membrane (PS) on oxidative stress markers such as ADMA. Methods. Thirty-one HD patients were enrolled to this investigation. They were allocated into two groups: In the PSE group (n= 16), PSE was used for 6 months, followed by PS for an additional 12 months; in the PS group (n= 15), PS was used for the entire observation period. Plasma ADMA, oxidized low density lipoprotein (Ox-LDL) and malondialdehyde LDL (MDA-LDL) levels were measured at baseline, 3, 6, 12 and 18 months. Plasma ADMA in peritoneal dialysis (PD) patients and in healthy individuals was also measured. Results. Predialysis concentrations of ADMA (0.72± 0.13nmol/ml) were significantly higher in the HD group than in both PD patients (0.63±0.10nmol/ml,P<0.01) and healthy individuals (0.44±0.01nmol/ml, P<0.0001). Treatment with PSE for 6 months significantly reduced predialysis levels of ADMA (0.54±0.09nmol/ ml) compared with baseline (0.74±0.12nmol/ml; P<0.01). Predialysis levels of Ox-LDL and MDA-LDL after 6 months therapy with PSE were also significantly lower than baseline values. Treatment with PS subsequent to treatment with PSE again increased ADMA, Ox-LDL and MDA-LDL back to baseline levels. In the PS group, ADMA, Ox-LDL and MDA-LDL levels remained unchanged during the entire treatment period of 18 months. Conclusions. We confirmed that use of PSE reduced ADMA that had accumulated in HD patients. This finding indicates that PSE exerts anti-oxidant activity. A randomized controlled study will be required to determine whether PSE prevents cardiovascular diseases and other dialysis-related complications by reducing oxidative stress.
AB - Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and an independent predictor of overall mortality and cardiovascular outcome in haemodialysis (HD) patients. In the present study, we compared the effects of a vitamin E-coated polysulfone membrane (PSE) and a non-vitamin E-coated polysulfone membrane (PS) on oxidative stress markers such as ADMA. Methods. Thirty-one HD patients were enrolled to this investigation. They were allocated into two groups: In the PSE group (n= 16), PSE was used for 6 months, followed by PS for an additional 12 months; in the PS group (n= 15), PS was used for the entire observation period. Plasma ADMA, oxidized low density lipoprotein (Ox-LDL) and malondialdehyde LDL (MDA-LDL) levels were measured at baseline, 3, 6, 12 and 18 months. Plasma ADMA in peritoneal dialysis (PD) patients and in healthy individuals was also measured. Results. Predialysis concentrations of ADMA (0.72± 0.13nmol/ml) were significantly higher in the HD group than in both PD patients (0.63±0.10nmol/ml,P<0.01) and healthy individuals (0.44±0.01nmol/ml, P<0.0001). Treatment with PSE for 6 months significantly reduced predialysis levels of ADMA (0.54±0.09nmol/ ml) compared with baseline (0.74±0.12nmol/ml; P<0.01). Predialysis levels of Ox-LDL and MDA-LDL after 6 months therapy with PSE were also significantly lower than baseline values. Treatment with PS subsequent to treatment with PSE again increased ADMA, Ox-LDL and MDA-LDL back to baseline levels. In the PS group, ADMA, Ox-LDL and MDA-LDL levels remained unchanged during the entire treatment period of 18 months. Conclusions. We confirmed that use of PSE reduced ADMA that had accumulated in HD patients. This finding indicates that PSE exerts anti-oxidant activity. A randomized controlled study will be required to determine whether PSE prevents cardiovascular diseases and other dialysis-related complications by reducing oxidative stress.
KW - ADMA
KW - Haemodialysis
KW - Oxidative stress
KW - Polysulfone
KW - Vitamin E-coated
UR - http://www.scopus.com/inward/record.url?scp=27944486739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27944486739&partnerID=8YFLogxK
U2 - 10.1093/ndt/gfi121
DO - 10.1093/ndt/gfi121
M3 - Article
C2 - 16221689
AN - SCOPUS:27944486739
VL - 20
SP - 2775
EP - 2782
JO - Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress
JF - Proceedings of the European Dialysis and Transplant Association - European Renal Association. European Dialysis and Transplant Association - European Renal Association. Congress
SN - 0931-0509
IS - 12
ER -
